Examining a Novel Fas Receptor Inhibitor for Dry AMD

Time: 10:30 am
day: Conference Day Two


  • Discussing the pre-clinical data regarding the role of Fas in retinal disease and AMD
  • Discussing the development of ONL1204, a novel inhibitor of the Fas receptor
  • Discussing the results of the Phase 1 study of ONL1204 in patients with GA secondary to AMD and the upcoming Phase 2 trial